| Literature DB >> 32430011 |
Shuqi Guo1, Yunxiao Wang1, Wei Wang1, Hongbo Hu1,2, Xuehong Zhang3.
Abstract
BACKGROUND: 2-Acetamidophenol (AAP) is an aromatic compound with the potential for antifungal, anti-inflammatory, antitumor, anti-platelet, and anti-arthritic activities. Due to the biosynthesis of AAP is not yet fully understood, AAP is mainly produced by chemical synthesis. Currently, metabolic engineering of natural microbial pathway to produce valuable aromatic compound has remarkable advantages and exhibits attractive potential. Thus, it is of paramount importance to develop a dominant strain to produce AAP by elucidating the AAP biosynthesis pathway. RESULT: In this study, the active aromatic compound AAP was first purified and identified in gene phzB disruption strain HT66ΔphzB, which was derived from Pseudomonas chlororaphis HT66. The titer of AAP in the strain HT66ΔphzB was 236.89 mg/L. Then, the genes involved in AAP biosynthesis were determined. Through the deletion of genes phzF, Nat and trpE, AAP was confirmed to have the same biosynthesis route as phenazine-1-carboxylic (PCA). Moreover, a new arylamine N-acetyltransferases (NATs) was identified and proved to be the key enzyme required for generating AAP by in vitro assay. P. chlororaphis P3, a chemical mutagenesis mutant strain of HT66, has been demonstrated to have a robust ability to produce antimicrobial phenazines. Therefore, genetic engineering, precursor addition, and culture optimization strategies were used to enhance AAP production in P. chlororaphis P3. The inactivation of phzB in P3 increased AAP production by 92.4%. Disrupting the phenazine negative regulatory genes lon and rsmE and blocking the competitive pathway gene pykA in P3 increased AAP production 2.08-fold, which also confirmed that AAP has the same biosynthesis route as PCA. Furthermore, adding 2-amidophenol to the KB medium increased AAP production by 64.6%, which suggested that 2-amidophenol is the precursor of AAP. Finally, by adding 5 mM 2-amidophenol and 2 mM Fe3+ to the KB medium, the production of AAP reached 1209.58 mg/L in the engineered strain P3ΔphzBΔlonΔpykAΔrsmE using a shaking-flask culture. This is the highest microbial-based AAP production achieved to date.Entities:
Keywords: 2-Acetamidophenol; Aromatic chemicals; Arylamine N-acetyltransferase; Biosynthesis; Pseudomonas chlororaphis
Year: 2020 PMID: 32430011 PMCID: PMC7236291 DOI: 10.1186/s12934-020-01364-7
Source DB: PubMed Journal: Microb Cell Fact ISSN: 1475-2859 Impact factor: 5.328
Fig. 1Phenotype and HPLC profile of the P. chlororaphis HT66 wild-type and gene phzB derived mutants. A phenotype: (a) wild-type strain P. chlororaphi HT66, (b) phzB-inactivated mutant HT66ΔphzB, and (c) phzB genetic complementation strain HT66ΔphzB-pBBR phz’-phzB. B HPLC profile of wild-type and gene phzB derived mutants
Fig. 2Mass spectrometry of purified compound AAP. The calculated mass of AAP was m/z 152.0706 for [M (C8H9NO2) + H]+. The exact mass m/z 152.0727 was purified compound AAP. The Mass m/z 110.0621 was AAP losing the acetyl group*
Fig. 3The genes involved in AAP biosynthesis pathway in P. chlororaphis HT66 analyzed by gene deletion
Fig. 4The production of AAP under the condition of adding different concentrations of 2-aminophenol and Anthranilic acid
Fig. 5In vitro catalysis of NATs to 2-aminophenol. A SDS-PAGE of protein NATs, 32.2KDa. B (a) The standard of AAP, (b) catalysis system without NATs, and (c) catalysis system with NATs. AAP: 2-acetamidophenol; 2-AP: 2-aminophenol
Fig. 6Proposed biosynthesis pathway of AAP in P. chlororaphis HT66. ADIC: amino-deoxyisochorismic acid; DHHA: trans-2,3-dihydro-3-hydroxyanthranilic acid; AOCHC: 6-amino-5-oxocyclohex-2-ene-1-carboxylic acid; PDC: phenazine-1,6-dicarboxylic acid; PCA: phenazine-1-carboxylic; PHZ: phenazine; AAP: 2-acetamidophenol
Production of 2-acetamidophenol in the P. chlororaphis HT66 wild-type and derived strains (P < 0.05)
| Entry | HT66 | Fe3+ (mM) | 2-aminophenol (mM) | AAP concentration (mg/L) |
|---|---|---|---|---|
| 1 | WT | 0.00 ± 0.00 g | ||
| 2 | HT66Δ | 236.89 ± 4.28 f | ||
| 3 | P3Δ | 455.67 ± 59.59 e | ||
| 4 | P3Δ | 2 | 750.13 ± 0.97 c | |
| 5 | P3Δ | 728.62 ± 13.99 d | ||
| 6 | P3Δ | 2 | 1 | 1130.86 ± 22.42 b |
| 7 | P3Δ | 2 | 5 | 1209.58 ± 5.74 a |
Strains and plasmids used in this study
| Strains and plasmids | Relevant gene type | Reference/source |
|---|---|---|
| Strains | ||
| DH5α | Lab stock | |
| | Res− pro mod+ integrated copy of RP4, mob+, used for incorporating constructs into | Lab stock |
| BL21(DE3) | Host strain for pET28a | Invitrogen |
| HT66 | This study | |
| P3 | A mutant from HT66 with a high PCN production, Ampr Spr | This study |
| HT66Δ | This study | |
| HT66Δ | This study | |
| HT66Δ | This study | |
| HT66Δ | This study | |
| HT66Δ | This study | |
| HT66Δ | This study | |
| HT66Δ | This study | |
| P3Δ | This study | |
| P3Δ | This study | |
| Plasmid | ||
| pK18mobsacB | Broad-host-range gene replacement vector, | Lab stock |
| pBBR1MCS | T7 expression vector, Kanr | Lab stock |
| PET-28a (+) | T7 promoter, Kanr, expression vector | Novagen |
| pBBR-phz’- | Gene complementation vector, pBBR1MCS containing a 534 bp | This study |
| PET28a (+)- | pET28a (+) containing | This study |
aAmpr, Spr, and Kanr represent ampicillin, spectinomycin, and kanamycin resistance, respectively